Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry

AIMS: Worldwide, rivaroxaban is increasingly used for stroke prevention in atrial fibrillation (SPAF) but little is known about the rates of or reasons for rivaroxaban discontinuations in daily care. Using data from a prospective, non-interventional oral anticoagulation (NOAC) registry, we analysed...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Europace
Asıl Yazarlar: Beyer-Westendorf, Jan, Förster, Kati, Ebertz, Franziska, Gelbricht, Vera, Schreier, Thomas, Göbelt, Maria, Michalski, Franziska, Endig, Heike, Sahin, Kurtulus, Tittl, Luise, Weiss, Norbert
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2015
Konular:
Clinical Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4381834/
https://ncbi.nlm.nih.gov/pubmed/25694537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/europace/euu319
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller